Document resource
Objective Our objective is to evaluate how the results of the MISTIE III trial affected intracerebral hemorrhage (ICH) evacuation procedure volumes.Methods We utilized an aggregated dataset that contains Medicare Part B procedure data from 2015 to 2023. We first identified MISTIE III as the major ICH evacuation randomized controlled trial published during this time period. We found the normalized volume of minimally invasive catheter drainage (MICD) procedures, supratentorial craniotomies, and infratentorial craniotomies for ICH evacuation using their respective Current Procedure Terminology codes. We normalized the volumes by finding the percentage of all neurosurgical procedures that were composed of ICH evacuation procedures for each year. We used an interrupted time series (ITS) to find statistically significant changes in volumes after 2019, when the MISTIE III results were published.Results After the publication of the MISTIE III results in 2019, normalized MICD volumes increased in the long-term compared to the pre-2019 trend (p<0.001) based on the ITS analysis. The normalized MICD volumes decreased by 36.2% from 2013 to 2019 but increased by 237.0% from 2019 to 2023. However, supratentorial and infratentorial craniotomy procedure volumes, in addition to overall ICH evacuation procedure volumes across all procedure types, showed no long-term significant change (p=0.091, p=0.18, p=0.68, respectively).Conclusions The results of MISTIE III did not show a favorable benefit of MICD over medical management for ICH in terms of the primary outcome of functional independence. We found that, despite these results, MICD evacuation procedure volumes increased significantly after the publication of the MISTIE III results.Disclosures G. Branscom: None. E. Ren: None. K. Srinivasan: None. M. Lemonick: None. M. Carr: None. T. Choudhri: None. L. Hao: None. R. Carpenter: None. J. Lee: None.Abstract P-001 Figure 1